



4th Foresight Training Course

**EVIDENCES FOR RATIONAL THERAPIES:
FROM NEWBORN TO ELDERLY POPULATION**

1-3 September 2011 • Rome, Italy

Gianni Benzi Pharmacological Research Foundation

Dear Colleagues,

for the 4th Foresight Training Course we chose Rome, where the ancient and the modern meet in every field.

This year the Course also applies for the Italian system of educational credits (ECM) for healthcare professionals. The Gianni Benzi Foundation is, in fact, authorised to assign ECM credits according to the latest Italian law (provider n° 1595) for on site educational activities and e-learning courses.

The Foresight Training Courses are international events addressed to Medical Directors, R&D Managers, Pharmacovigilance Managers, Clinical Research Associates, Clinical Project Managers/ Leaders, Regulatory Affairs Operators, Market Access Operators, Statisticians, Information Technology Operators and Data Managers of Pharmaceutical Industries, but also to Managing Directors and Researchers (Medical and not-medical) of Research Centers, Professors and Students, Business Development Managers, Medical Directors, Project Managers, Clinical Research Associates working in CROs, and finally Managing Directors working in the Biotech field. The Courses are aimed to underline the more recent and stimulating debates open in the field of the European Pharmaceutical System and to contribute actively to them.

In line with the previous editions, the Course is inspired by the European trends concerning pharmaceuticals, with special attention to the advancement in the Clinical Trials methodology and other studies supporting drug development and post-marketing drugs use.

The current debate on how to support and consolidate clinical evidences in different settings and different diseases by collecting useful data from the drug developmental phase to post-marketing use, will be addressed having as example the working methodology already validated by EMA and other National Authorities.

As other editions, the Course gains its strength by the involvement of all the interested stakeholders (Regulators, Researchers, Physicians, Health Professionals, Private and Public Companies, Patient Associations) and by the collaboration with such organisations as the Children's Memorial Health Institute of Warsaw, the National Center for Biological Research (CNRB), the Middle European Association for Regulatory Affairs (MEGRA), the Italian Society of Regulatory Activities (SIAR) and the Task Force in Europe for Drug Development in the Young (TEDDY). Farindustria, the Italian pharmaceutical industry association, contributed also to the realisation of this Course with an educational grant.

We sincerely hope that you will be able to participate in the Course and enjoy contents, discussions and social dinners.

With our best wishes,

Adriana Ceci

'Gianni Benzi' Foundation
President



Enrico Bosone

'Gianni Benzi' Foundation
SIAR Representative in the Board



1-3 SEPTEMBER 2011 • ROME • ITALY

4th FORESIGHT TRAINING COURSE

**EVIDENCES FOR RATIONAL THERAPIES:
FROM NEWBORN TO ELDERLY POPULATION**

organised by
the 'Gianni Benzi' Pharmacological Research Foundation

Scientific collaboration:

- **Children's Memorial Health Institute of Warsaw**
- **CNRB - National Center for Biological Resources**
- **MEGRA - Middle European Association for Regulatory Affairs**
- **SIAR - Italian Society of Regulatory Activities**
- **TEDDY - Task Force in Europe for Drug Development in the Young**

Educational Grant from



FARMINDUSTRIA

BACKGROUND

This fourth Course of the Gianni Benzi Foundation is inspired by the European Programs concerning Health, with special attention to the EMA Road-Map 2010-2015, and to the national Health Plans (such as the Italian oncologic plan 2011-2013). In fact, the European activities take into account the national issues and, on the other hand, the local level is influenced by the outcomes of the European Process.

Health Authorities' decisions are based on the "regulatory sciences" that include the **scientific evidences** provided both by "basic and applied medicinal science", continuously updated. Up to now scientific evidences are collected mainly during the drug developmental process, in particular through the pre-marketing registrative clinical/non-clinical trials. However, the rules and methodologies to assess scientific evidences could vary in accordance with relevant patients characteristics - such as age (from birth to elderly), sex, geographic and social features, etc. - or disease characteristics (chronic versus acute, infective versus degenerative, immunological, oncological, etc.), as well as product characteristics (biological versus chemical, AT, etc.).

In addition, when relevant unmet medical needs are concerned and positive preliminary data are available, timely management of regulatory decisions is of paramount importance. For that reason, allowing access to therapies without having yet the complete knowledge of the consequences of the therapy can be acceptable in some cases.

In these cases the subsequent collection of clinical evidences, supplied by phase IV CTs, observational studies, active and passive pharmacovigilance, registries of therapies and/or diseases, can help in the definition of the best therapeutic strategy.

Three strategic areas are depicted in the EMA Road-Map: the **unmet public-health needs**, **access to therapies** and **rational use of therapies**. They can be taken as a common denominator of all the strategies aiming to improve the Health in each Member State, both in Europe and in the World.

The oncology field represents a significant example in this sense (see the Italian National Oncologic Plan 2011-2013 as an example) since all these approaches are applied and all these efforts are translated in dedicated plans and guides covering again 'by birth to elderly'.

The fourth Course of the Gianni Benzi Foundation wishes to start from this picture having the objective to examine the different phases of R&D for new therapies, to underline the opportunities made available by the existing collaborative international networks, to stimulate additional collaborative efforts having as example the working methodology already validated by EMA and other national Authorities like AIFA. Special attention will be focused on the advancement in the Clinical Trials methodology and other studies supporting drug development and post-marketing drug uses (revision of CT Directive, Pharmacovigilance implementation, EudraCT and so on).

COURSE DIRECTORS

Enrico Bosone	SIAR representative in the Gianni Benzi Foundation Managing Board; Regulatory and Public Affairs Director, Celgene srl
Marek Migdal	Deputy Head of PICU, Children's Memorial Health Institute, Warsaw; member of Paediatric Committee (PDCO), EMA
Paola Baiardi	CVBF representative in the Gianni Benzi Foundation Board; member of the Paediatric Working Group-AIFA
Mariana Catapano	GISF Director and Regulatory Science Expert



Organising Secretariat

Rossella Conte

secretary@benzifoundation.org

Scientific Secretariat

Viviana Giannuzzi

vg@benzifoundation.org

Communication Services

Rosy Piaggione

info@benzifoundation.org

PROGRAM

01.09.2011

Welcome Session in the presence of the Authorities

Strategic areas for therapies in Europe: Health Authorities, Academy, Industry facing unmet medical needs (9:30 am – 1:00 pm)

Chairs: Vittorio Silano - Walter Bianchi

Introduction to the Course	A. Ceci - E. Bosone
EMA Road Map perspectives and present status	Vincenzo Salvatore
How the regulatory system can be attuned to science	Ian Hudson
How to address orphan therapeutic needs	Kerstin Westermarck
How to integrate research needs and children protection	Daniel Brasseur
How Science must reduce human sufferings	Pawel Januszewicz
Role of Industry	Antonio Del Santo
Role of research networks	Carlo Giaquinto

Discussion

1:00 pm Lunch

Session I - How to provide scientific evidences: different approach for different settings (2:00 pm - 6:00 pm)

Patients population

Chairs : Jerry Zeldis - Mariana Catapano

PIPs and paediatric population: current status

Neonatal and paediatric intensive care

CTs designed for old people

CTs in fertile pregnant women and adolescents

Appropriate formulations:

from neonates to old patients

Non clinical studies

Gunter Egger

Marek Migdal

Simonetta Alvino

Viveca Odling

Siri Wang

Annarita Meneguz

Discussion

4:00 pm Coffee-break

Specific diseases

Chairs: Walter Bianchi - Marek Migdal

Haematology-oncology

Paediatric oncology

Immunology

Rare diseases

Neglected diseases

Daniele Alberti

Paolo Paolucci

Paolo Rossi

Carlos Camozzi

Jerry Zeldis

Discussion

6:00 pm Rome tour and dinner



02.09.2011

Round Table I - The future European Union Legislation for CT (8:30 am - 11:00 am)

Chairs: Daniel Brasseur - Leonardo Santi

Presentations:

Antonio Galluccio

Which role for EU databases in clinical research?

Ian Hudson

Are the Clinical Trials and the GCP Directives to be changed?

Discussants:

COMP (Committee for Orphan Medicinal Products - EMA)

Kerstin Westermark

EUCROF (European CRO Federation)

Martine Dehlinger-Kremer

CNRB (National Center for Biological Research)

Dino Amadori

EMA (European Medicines Agency)

Gunter Egger

GRIP (Global Research in Paediatrics) & TEDDY

Adriana Ceci

EURORDIS (Rare Diseases in Europe)

Dorica Dan

INDUSTRY

Giuseppe Caruso

Fabien Peuvrelle

Discussion

11:00 am Coffee-break



Session II - Behind Registrative Clinical Trials: how to use different tools to increase clinical evidences (11:15 am - 1:00 pm)

Chairs: Enrico Bosone - Dorica Dan

Non-interventional studies from the perspective of the Regulatory Authorities	Antonio Galluccio
Health Records databases, pharmacoepidemiology and drug development	Miriam Sturkenboom
EPIRARE: European Platform for Rare Disease Registries	Domenica Taruscio
Non conventional studies and orphan drug evaluation	Paola Baiardi
Observational studies inspired by Treatments' Registries	Antonio Del Santo
PAH in children	Malgorzata Zuk

Discussion

1:00 pm Lunch

Session III – Behind the drug development: what is at the door? (2:00 pm – 3:30 pm)

Chairs: Rodolfo Paoletti - Siri Wang

Introduction: *Menotti Calvani*

Generics as a tool	Pia Furlani
Nutraceuticals: which role for human health?	Andrea Poli
Are Biosimilar a new or an old drug?	Chris Walker
The role of Biotechnologies	Domenico Criscuolo

Discussion

3:30 pm Coffee-break

Session IV – Rational use of Medicines: Pharmacovigilance in the light of the forthcoming legislation (3:45 pm – 6:00 pm)

Chairs: Miriam Sturkenboom - Walter Bianchi

Legal aspects and implementation at EMA level

Vincenzo Salvatore

Implementation at national level

Fernanda Ferrazin

Active pharmacovigilance in paediatrics

Antje Neubert

Pharmacovigilance and market access

Paolo Biffignandi

Discussion

6:00 pm Rome tour and dinner



03.09.2011

Session V – Access to therapies for patients and health professionals. The true innovation is the improvement of the clinical benefit (8:30 am – 11:15 am)

Chairs: Renza Galluppi - Viveca Odling

Access to therapy in rare conditions

Dorica Dan

Met and unmet medical needs for old people

Agnes Gyurasics

Women and therapeutic needs

Flavia Franconi

Met and unmet medical needs in haematology

Robin Foà

Met and unmet medical needs in neurology

Luca Massacesi

Met and unmet medical needs in oncology

Paolo Marchetti

Needs in paediatric oncology

Bozena Dembowska-Baginska

Discussion

Round Table II – Models for the assessment of B/R ratio, Comparative Benefit/Risk ratio, cost-benefit and HTA experiences at international (EUnetHTA) and national levels (11:15 am – 12:30)

Chairs: Adriana Ceci - Gunter Egger

Presentation:

Jacek Gralinski

Public Health needs at national level

Claudio Jommi

HTA experiences at international and national level

Discussants:

Anna Cieslik

Olof Tyden

Enrico Bosone

Discussion

12:30 Closing Remarks: Course Directors

1:00 pm Light Lunch

SPEAKERS LIST

SURNAME	NAME	AFFILIATION
Alberti	Daniele	Novartis Farma S.p.A., Oncology Medical Director, Italy
Alvino	Simonetta	Pharmanet, Medical Director, Italy
Amadori	Dino	Institute for the Study and Treatment of Cancer (Forli), Scientific Director, Italy
Baiardi	Paola	Consortium for Biological and Pharmacological Evaluations, Director, Italy
Biffignandi	Paolo	VI.REL Pharma S.a.s. - Regulatory Affairs Consultancy, Director, Italy
Bianchi	Walter	Italian Society of Regulatory Affairs, President, Italy
Bosone	Enrico	'G. Benzi' Pharmacological Research Foundation, Italian Society of Regulatory Affairs Representative in the Board, Italy
Brasseur	Daniel	European Medicines Agency, Chair Paediatric Committee, Belgium
Calvani	Menotti	Fondazione SigmaTau, Vice-President, Italy
Camozzi	Carlos	AMT Biopharmaceuticals, Chief Medical Officer, France
Caruso	Giuseppe	Farminindustria, Scientific and Innovation Area Director, Italy
Catapano	Mariana	Italian Group for Pharmacoeconomics Studies, Director, Italy
Ceci	Adriana	'G. Benzi' Pharmacological Research Foundation, President, Italy
Cieslik	Anna	Polish National Medicines Institute, Head Documentation Assessment Department, Poland
Criscuolo	Domenico	Genovax, Chief Executive Officer, Italy
Dan	Dorica	EURORDIS, Board Member, Romania
Del Santo	Antonio	Roche S.p.A. Italy, Medical Director, Italy
Dembowska-Baginska	Bozena	European Medicines Agency, Committee for Orphan Medicinal Products Member, Poland
Dehlinger-Kremer	Martine	ReSearch Pharmaceutical Services (RPS), Vice President Global Regulatory Affairs, Germany
Egger	Gunter	European Medicines Agency, Scientific Administrator, UK
Ferrazin	Fernanda	Italian Medicines Agency, Head of the Post-Marketing Surveillance Area, Italy
Foà	Robin	'Sapienza' University of Rome, Head of Hematology Division, Italy
Franconi	Flavia	Italian Society of Pharmacology, Gender-oriented Group Coordinator, Italy
Furlani	Pia	DOC Generici srl, Regulatory Affairs Director, Italy
Galluccio	Antonio	National Monitoring Centre on Clinical Research with Medicines (OsSC), Scientific Coordinator, Italy
Galluppi	Renza	UNIAMO, Italian Federation Rare Diseases Onlus, President, Italy

SURNAME	NAME	AFFILIATION
Giaquinto	Carlo	GRIP and PENTA Networks Coordinator, Italy
Gralinski	Jacek	The Children's Memorial Health Institute, Clinical Director, Poland
Gyurasics	Agnes	European Medicines Agency, Committee for Medicinal Products for Human Use Member, Hungary
Hudson	Ian	European Medicines Agency, Committee for Medicinal Products for Human Use Member, UK
Januszewicz	Pawel	Polish National Medicines Institute, Head of Paediatric Pharmacology Unit, Poland
Jommi	Claudio	Bocconi University - School of Economics, Associate Professor, Department of Institutional Analysis and Public Management, Italy
Marchetti	Paolo	University Hospital 'Sant'Andrea', Head of Oncology Unit, Italy
Massacesi	Luca	Professor of Neurology, Department of Neurological and Psychiatric Sciences, University of Florence, Italy
Meneguz	Annarita	Italian National Institute of Health, Head of Unit of Biochemical Pharmacology and Technical Scientific Advice, Italy
Migdal	Marek	European Medicines Agency, Paediatric Committee Member, Poland
Neubert	Antje	University Hospital Erlangen, Head of Paediatric Clinical Study Center, Germany
Od lind	Viveca	European Medicines Agency, Paediatric Committee, Member, Sweden
Paoletti	Rodolfo	Nutrition Foundation of Italy, President, Italy
Paolucci	Paolo	European Medicines Agency, Paediatric Committee, Member, Italy
Peuvrelle	Fabien	Celgene R&D Sàrl, Regulatory Operations Europe Regulatory Affairs Director, Switzerland
Poli	Andrea	Nutrition Foundation of Italy, Scientific Director, Italy
Rossi	Paolo	European Medicines Agency, Paediatric Committee Member, Italy
Salvatore	Vincenzo	European Medicines Agency, Head of Legal Sector, UK
Santi	Leonardo	National Center for Biological Resources, president, Italy
Silano	Vittorio	'G. Benzi' Pharmacological Research Foundation, Scientific Commission President, Italy
Sturkenboom	Miriam	Erasmus University Medical Center, Professor of Pharmaco-epidemiology, The Netherlands
Taruscio	Domenica	Italian National Institute of Health, National Centre for Rare Diseases Director, Italy
Tyden	Olof	EUREDA, Strategic Consulting International Pharmaceutical Industry, Sweden
Wang	Siri	European Medicines Agency, Head of PDCO Formulation Subgroup, Norway
Walker	Chris	Amgen, Director for International Regulatory Affairs, UK
Westermarck	Kerstin	European Medicines Agency, Committee for Orphan Medicinal Products President, Sweden
Zeldis	Jerry	Celgene Global Health and Celgene Corporation, CEO and Chief Medical Officer, USA
Zuk	Malgorzata	Children's Memorial Health Institute, Head of Cardiology Department, Poland

SURNAME NAME

AFFILIATION

Please return the form to GIANNI BENZI PHARMACOLOGICAL RESEARCH FOUNDATION

Tel. +39 080 9643146 • Fax +39 080 9643144 • email: secretary@benzifoundation.org

Name _____ Surname _____

Date and place of birth _____ Taxpayer number _____

Address _____

Post code _____ Town _____ Country _____

Tel. _____ Fax _____ Email _____

Organisation _____ Job title _____

Address of Organisation _____

Post code _____ Town _____ Country _____

Tel. _____ Fax _____ Email _____

VAT number _____ Taxpayer number _____

	Full Course	Full Course + Dinners	Full Course + Dinners + Hotel (2 nights)
Standard	€ 2.250	€ 2.400	€ 2.700
Graduate Students	€ 600	€ 750	€ 1.050

Method of Payment

Bank transfer to: Gianni Benzi Foundation

IBAN code: IT 63 10101041750100000001097 – BIC / SWIFT code: IBSPITNA

Date

Signature

PRIVACY

In conformity with the Italian Legislative Decree n. 196, art. 13 of 30 June 2003, the "Gianni Benzi" Foundation informs you that the personal data will be handled for organizational purposes and for sending free of charges the documentation related to other congresses or initiatives organized by the Gianni Benzi Foundation only and will be by no means released to third parties. As provided by art. 7 of the Decree n. 196, art. 13 of 30 June 2003, you can contact Gianni Benzi Foundation for further information (crossing out, correction, integration of data). If you agree, please give us your authorization.

I authorized the handling of my personal data for the above mentioned aims:

☐ YES

☐ NO

Date

Signature

HOW TO REACH ROME

Leonardo da Vinci (Fiumicino Rome) and G. B. Pastine (Ciampino Rome)
are the airports of Rome

www.adr.it

There are several bus services that link Rome to its airports

www.sitbusshuttle.it

The main railway station of Rome is Termini

The Underground system is connected to the railway station, and there are other railway
connections between Airports and Termini station

www.trenitalia.com

Radio Taxi

consorzio AssoTaxi - 199/41.40.4

coop. 3570 Autoradiotaxi Romana +39 06 3570

Radio Taxi 6645 +39 06 6645

soc. La Capitale +39 06 4994

soc. Tevere +39 06 4157

soc. Cosmo +39 06 88177

coop. Samarcanda +39 06 5551

COURSE LOCATION

Aran Mantegna Hotel


Via Mantegna, 130

00147 Roma, EUR - Italy

Email: mantegna@aranhotels.com

Phone: +39 06 98 95 21

Fax: +39 06 98 95 27 99



Aran Mantegna Hotel's front entrance – Rome



A view of the Coliseum – Rome

ORGANISED BY



GIANNI BENZI

PHARMACOLOGICAL RESEARCH
FOUNDATION

IN COLLABORATION WITH



INSTYTUT "POMNIK - CENTRUM ZDROWIA DZIECKA"
THE CHILDREN'S MEMORIAL HEALTH INSTITUTE
www.czd.waw.pl



EDUCATIONAL GRANT FROM



FARMINDUSTRIA

GIANNI BENZI PHARMACOLOGICAL RESEARCH FOUNDATION
VIA ABATE EUSTASIO 30 • 70010 BA ITALY

WWW.BENZIFOUNDATION.ORG • INFO@BENZIFOUNDATION.ORG

PHONE +39 080 9643146 • FAX +390809643144

VAT: IT 06780820723 • TAXPAYER'S CODE: IT 93347800729